Application of MicroRNA in diagnosis and treatment of ovarian cancer

Kouji Banno, Megumi Yanokura, Miho Iida, Masataka Adachi, Kanako Nakamura, Yuya Nogami, Kiyoko Umene, Kenta Masuda, Iori Kisu, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Daisuke Aoki

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

Original languageEnglish
Article number232817
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

MicroRNAs
Ovarian Neoplasms
Therapeutics
Ribonuclease III
Neoplasm Metastasis
Chemotherapy
Gene Silencing
Biomarkers
Regulator Genes
Tumor Biomarkers
Drug Resistance
Epigenomics
Gene expression
Pharmaceutical Preparations
Transfection
Carcinogenesis
Down-Regulation
Genes
Tissue
Morbidity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Application of MicroRNA in diagnosis and treatment of ovarian cancer. / Banno, Kouji; Yanokura, Megumi; Iida, Miho; Adachi, Masataka; Nakamura, Kanako; Nogami, Yuya; Umene, Kiyoko; Masuda, Kenta; Kisu, Iori; Nomura, Hiroyuki; Kataoka, Fumio; Tominaga, Eiichiro; Aoki, Daisuke.

In: BioMed Research International, Vol. 2014, 232817, 2014.

Research output: Contribution to journalArticle

Banno, Kouji ; Yanokura, Megumi ; Iida, Miho ; Adachi, Masataka ; Nakamura, Kanako ; Nogami, Yuya ; Umene, Kiyoko ; Masuda, Kenta ; Kisu, Iori ; Nomura, Hiroyuki ; Kataoka, Fumio ; Tominaga, Eiichiro ; Aoki, Daisuke. / Application of MicroRNA in diagnosis and treatment of ovarian cancer. In: BioMed Research International. 2014 ; Vol. 2014.
@article{3e6369050e3a4cc695c796e5670a26d6,
title = "Application of MicroRNA in diagnosis and treatment of ovarian cancer",
abstract = "Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.",
author = "Kouji Banno and Megumi Yanokura and Miho Iida and Masataka Adachi and Kanako Nakamura and Yuya Nogami and Kiyoko Umene and Kenta Masuda and Iori Kisu and Hiroyuki Nomura and Fumio Kataoka and Eiichiro Tominaga and Daisuke Aoki",
year = "2014",
doi = "10.1155/2014/232817",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Application of MicroRNA in diagnosis and treatment of ovarian cancer

AU - Banno, Kouji

AU - Yanokura, Megumi

AU - Iida, Miho

AU - Adachi, Masataka

AU - Nakamura, Kanako

AU - Nogami, Yuya

AU - Umene, Kiyoko

AU - Masuda, Kenta

AU - Kisu, Iori

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Tominaga, Eiichiro

AU - Aoki, Daisuke

PY - 2014

Y1 - 2014

N2 - Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

AB - Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

UR - http://www.scopus.com/inward/record.url?scp=84900345484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900345484&partnerID=8YFLogxK

U2 - 10.1155/2014/232817

DO - 10.1155/2014/232817

M3 - Article

C2 - 24822185

AN - SCOPUS:84900345484

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 232817

ER -